TERT and cancer: The current study incorporated the evaluation of the assay for diagnostic tumor variants across the entire coding domain of 523 genes plus the TERT promoter region, demonstrating high concordance with tumor tissue (Med = 96.9%) and high clinical sensitivity (91%) for therapeutic actionability among the diverse cancers encountered in the health system.